Dr. Kainthla grew up in Texas and received her initial medical training at UT Southwestern Medical Center in Dallas before completing her residency at Baylor College of Medicine in Houston, TX. Her biochemistry background drove her interest in oncology research, and she returned to complete her hematology and medical oncology fellowship at UT Southwestern Medical Center. She currently specializes in malignant hematology and gastrointestinal oncology. Outside of medicine, Dr. Kainthla enjoys watching movies, spending time with her family, and playing/watching sports.
- Medical School
- UT Southwestern Medical School (2012)
- Baylor College of Medicine (2015), Internal Medicine
- UT Southwestern Medical Center (2018), Hematology Oncology
- Gastrointestinal Oncology
- Malignant Hematology
- Quality Improvement
- Adjuvant chemotherapy for ypT0N0M0 rectal cancer following chemoradiotherapy and total mesorectal excision.
- Kainthla R, Huerta S Anticancer Drugs 2016 Jul
- Dabrafenib for treatment of BRAF-mutant melanoma.
- Kainthla R, Kim KB, Falchook GS Pharmgenomics Pers Med 2014 7 21-9
- Regulation of telomerase alternative splicing: a target for chemotherapy.
- Wong MS, Chen L, Foster C, Kainthla R, Shay JW, Wright WE Cell Rep 2013 Apr 3 4 1028-35
Leukemia. In Handbook of Targeted Cancer Therapy
Kainthla R, Kadia TM, Pennaraju N (2015). Phildelphia, PA, Wolters Kluwer
Small Molecules in Oncology: Dabrafenib. In Recent Results in Cancer Research
Kainthla R, Kim, KB, Falchook GS (2014). Heidelberg, Springer
Honors & Awards
- Hematology/Oncology Chief Fellow Award
UT Southwestern (2017-2018)
- American Society of Clinical Oncology (2015)
- American Society of Hematology (2015)
- Dallas County Medical Society (2015)
- American Medical Association (2012)
- Texas Medical Association (2008)